Want to join the conversation?
$A said its Diagnostic and Genomics Group (DGG) delivered 5% core growth in 2Q16 against a difficult compare. The pathology business continues on its steady trajectory back to market growth rates, highlighted by a strong demand for a new PD-L1 companion and complementary diagnostics test. DGG's operating margin was flat versus a year ago at 15%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.